Laura Pat Svetkey, MD

Professor of Medicine
Director of Clinical Research
Vice-chair for Faculty Development & Diversity in the Department of Medicine
Campus mail Duke Box 3703, Durham, NC 27710
Phone (919) 681-6386
Email address svetk001@mc.duke.edu

Laura P. Svetkey, MD MHS is Professor of Medicine/Nephrology, Vice Chair for Faculty Development and Diversity in the Department of Medicine, and School of Medicine Faculty Ombudsperson. She is also the Director of Duke’s CTSA-sponsored internal career development award program (KL2) and the Investigator Development Core of Duke’s REACH Equity Disparities Research Center.

Dr. Svetkey has over 30 years of experience in the investigation of hypertension, obesity, and related areas, conducting NIH-sponsored clinical research ranging from behavioral intervention trials to metabolomics and genetics, with a consistent focus on prevention, non-pharmacologic intervention, health disparities and minority health. Her research has affected national guidelines, having served on the 2013 national Hypertension Guideline Panel (JNC) and the Lifestyle Guideline Working Group. She is an American Society of Hypertension certified hypertension specialist, and a member of the Association of American Physicians (AAP). She is the Associate Director, Core Director and Project PI of Duke’s REACH Equity Disparities Research Center.

As Department of Medicine Vice Chair for Faculty Development and Diversity, she implements a wide range of programs to enhance the experience and advancement of faculty and trainees, with particular emphasis on under-represented minorities and women.

As School of Medicine Faculty Ombudsperson, she helps faculty resolve concerns by providing confidential, impartial, informal guidance.

Education and Training

  • Fellow in General Internal Medicine, Medicine, Duke University, 1982 - 1983
  • Resident in Medicine, Medicine, Montefiore Medical Center, 1980 - 1982
  • Intern in Medicine, Medicine, Montefiore Medical Center, 1979 - 1980
  • M.D., Harvard University , 1979

Publications

Conlin, Paul R., Thomas P. Erlinger, Arline Bohannon, Edgar R. Miller, Lawrence J. Appel, Laura P. Svetkey, and Thomas J. Moore. “The DASH diet enhances the blood pressure response to losartan in hypertensive patients..” Am J Hypertens 16, no. 5 Pt 1 (May 2003): 337–42. https://doi.org/10.1016/s0895-7061(03)00056-6.

PMID
12745193
Full Text

ARD, J. “1-year follow-up results for participants who completed the DASH-Sodium trial.” In American Journal of Hypertension, 16:A158–59. Oxford University Press (OUP), 2003. https://doi.org/10.1016/s0895-7061(03)00500-4.

Full Text

SVETKEY, L. “Premier trial: BP effects of lifestyle interventions in subgroups.” In American Journal of Hypertension, 16:A28–A28. Oxford University Press (OUP), 2003. https://doi.org/10.1016/s0895-7061(03)00144-4.

Full Text

Appel, Lawrence J., Catherine M. Champagne, David W. Harsha, Lawton S. Cooper, Eva Obarzanek, Patricia J. Elmer, Victor J. Stevens, et al. “Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial..” Jama 289, no. 16 (April 23, 2003): 2083–93. https://doi.org/10.1001/jama.289.16.2083.

PMID
12709466
Full Text

Ard, Jamy D., Lori Carter-Edwards, and Laura P. Svetkey. “A new model for developing and executing culturally appropriate behavior modification clinical trials for African Americans..” Ethn Dis 13, no. 2 (2003): 279–85.

PMID
12785426
Scholars@Duke

Hegde, A., P. E. Klassen, D. W. Butterly, L. P. Svetkey, and A. Greenberg. “Effect of home monitoring on blood pressure and left ventricular hypertrophy in a hemodialysis cohort..” Journal of the American Society of Nephrology 13 (September 1, 2002): 210A-210A.

Scholars@Duke

Svetkey, L. P., D. G. Simons-Morton, M. A. Proschan, F. M. Sacks, P. R. Conlin, D. Harsha, and T. J. Moore. “Blood pressure control with DASH diet and reduced sodium intake.” In Hypertension, 40:437–38. LIPPINCOTT WILLIAMS & WILKINS, 2002.

Scholars@Duke

Akita, S., F. M. Sacks, W. M. Vollmer, L. P. Svetkey, and G. Kimura. “Effects of the dietary approaches to stop hypertension (DASH) diet on pressure-natriuresis relationship..” Journal of the American Society of Nephrology 13 (September 1, 2002): 607A-607A.

Scholars@Duke

Erlinger, T. P., P. R. Conlin, R. F. Mack, A. D. Bohannon, E. R. Miller, T. J. Moore, L. P. Svetkey, and L. J. Appel. “The impact of angiotensin II receptor blockade and the DASH diet on markers of endogenous fibrinolysis.” Journal of Human Hypertension 16, no. 6 (June 1, 2002): 391–97. https://doi.org/10.1038/sj/jhh/1001401.

Full Text

Pages